Sutro Biopharma Inc (NASDAQ:STRO) has prioritized three wholly owned pre-clinical programs in its next-generation ADC pipeline, indicating a focused strategic direction. The company's cash runway ...
Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. The company had revenue of $14.00 million for the quarter, compared to the consensus estimate of $10 ...
Sutro Biopharma , Inc. (NASDAQ:STRO), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs), has recently undergone a significant transformation in its ...
NASDAQ:STRO opened at $0.81 on Friday. Sutro Biopharma has a 12 month low of $0.81 and a 12 month high of $6.13. The firm has a market capitalization of $66.80 million, a PE ratio of -0.50 and a ...
Sutro Biopharma (NASDAQ:STRO) fell ~14% in the premarket on Friday after the company announced its decision to deprioritize its studies into the antibody-drug conjugate luveltamab tazevibulin as ...
On Monday, H.C. Wainwright analysts revised their stance on Sutro Biopharma (NASDAQ: NASDAQ:STRO), downgrading the stock from "Buy" to "Neutral." Alongside this change, they significantly lowered ...
Oppenheimer analyst Jay Olson downgraded Sutro Biopharma (STRO) to Perform from Outperform after the company reported Q4 results and announced restructuring plans. The firm is “not too surprised ...
SOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody ...
H.C. Wainwright downgraded Sutro Biopharma (STRO) to Neutral from Buy with a price target of $2, down from $12, after the company announced a strategic realignment focused on advancing its next ...
Sutro Biopharma :REFRaME-O1 Trial Data On Luvelta Shows Promise In Platinum-Resistant Ovarian Cancer
(RTTNews) - Sutro Biopharma Inc. (STRO) announced expanded data in a late-breaking oral presentation from the dose-optimization portion of the REFRaME-O1 trial with luveltamab tazevibulin (luvelta ...
On Friday, Truist Securities reaffirmed its Buy rating on Sutro Biopharma (NASDAQ: NASDAQ:STRO) shares but removed the price target previously set for the company. The decision followed Sutro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results